

Sample Letter: Brekiya autoinjector – Letter of Appeal for cluster headaches

This sample letter is for informational purposes only and may not meet all requirements for an appeal. Coverage criteria vary by health plan and patient benefits. Prescribers are solely responsible for ensuring the accuracy, medical necessity, and completeness of submitted information, as well as for all communications with the health plan. Use of this template does not guarantee approval or reimbursement and should not replace independent clinical judgment. Provided by Amneal Pharmaceuticals without obligation to prescribe its products.

[Insurance Company]

[Address Line 1]

[Address Line 2]

Re: Patient Name: _____

Policy ID: _____

Policy Group: _____

Date of Birth: _____

[Date]

Attn: [Medical/Pharmacy Director], [Department]

Re: URGENT Letter of Appeal for Brekiya® (dihydroergotamine mesylate) injection for [Plan Member Name]

Dear [Medical/Pharmacy Director or Appeals Department],

I am writing on behalf of my patient, [patient's name], who was denied coverage for Brekiya for the diagnosis of cluster headache. I ask for your urgent reconsideration of this decision.

[Patient's name] is a [patient's age]-year-old [male/female] patient, who has a diagnosis of cluster headache. I most recently saw [patient's name] on [date of visit]. Based on the patient's symptoms and history of medication use (as outlined below), it is medically necessary for them to undergo treatment with Brekiya. I am appealing this coverage decision, as I consider this medication critical to my patient's medical needs.

Brekiya is dihydroergotamine mesylate (DHE) indicated for the acute treatment of cluster headaches in adults. Brekiya is bioequivalent to subcutaneous D.H.E. 45®.¹ Brekiya is an autoinjector for at-home administration.²

Brekiya is necessary at this time for the following reasons:

- Sustained headache relief (approximately 24-72 hours)³
 - o In a study of 54 adult cluster headache patients admitted to the hospital on 64 occasions, 93% of episodic cluster patients remained completely headache free 3 months after IV DHE administration
- Brekiya is one of only 4 drugs that is FDA-approved for cluster headache^{1,2}
- Brekiya is the only form of DHE available as an autoinjector, with no assembly, priming the device, or refrigeration required. Since patients with cluster headache experience severe pain and eye swelling/drooping eyelid, or excessive tearing during attacks, the uncomplicated and straightforward administration process will benefit the patient and ensure they receive a full dose of medication^{1,2,4}

Patient's Clinical History:

Diagnosis:

- ☐ Acute Cluster Headache (ICD-10: G44.009)
- ☐ Other: [Diagnosis and ICD-10 code]

Sample Letter: Brekiya autoinjector – Letter of Appeal for cluster headaches

Previous Treatment History:

Medication	Dose	Outcome
[Medication]	[Dose]	Ineffective / Not tolerated
[Medication]	[Dose]	Ineffective / Not tolerated
[Medication]	[Dose]	Ineffective / Not tolerated

[Patient Name] has not responded adequately to other treatments and cannot use triptans due to [e.g., non-response/efficacy, adverse reactions]. Given this history, Brekiya is both clinically appropriate and medically necessary.

In summary, I am asking you to reconsider approving Brekiya for [patient's name], as I have concluded that it is critical to my patient's medical needs. Based on [his/her/their] these needs, Brekiya is vital to their treatment.

[A copy of the denial letter is included along with medical notes in response to the denial.]

Please contact my office at [office phone number] if any additional information is required to ensure approval of this appeal.

Sincerely,

[Your Name, Credentials]

[Your Practice/Institution Name]

[NPI Number]

[Reminder to list enclosures as appropriate: clinical documentation, copy of denial letter, treatment and medication history, full prescribing information (available at www.brekiya.com)]

References: 1. Data on file, Amneal Pharmaceuticals LLC. 2. Brekiya [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2025. 3. Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. *Headache*. 1991;31(8):525-532. doi:10.1111/j.1526-4610.1991.hed3108525.x4 4. Mayo Clinic. Cluster Headache. <https://www.mayoclinic.org/diseases-conditions/cluster-headache/symptoms-causes/syc-20352080>. Updated August 26, 2023. Accessed June 26, 2025.

Brekiya is a registered trademark of Amneal Pharmaceuticals LLC.

© 2025 Amneal Pharmaceuticals LLC.

PP-HCP-DHE-US-0004 10/2025